[8-K] ASP Isotopes Inc. Reports Material Event

Rhea-AI Filing Summary

ASP Isotopes Inc. (NASDAQ: ASPI) filed an 8-K dated July 25 2025 reporting that the Competition Commission of South Africa has conditionally approved ASPI’s offer to acquire all issued ordinary shares of Renergen Limited. The decision removes a key antitrust obstacle, but closing remains subject to unspecified conditions outlined by the regulator. No purchase price, financing details, or closing timetable are disclosed in the filing.

The related press release is furnished as Exhibit 99.1 (excluding its 5th and 6th paragraphs). No financial statements or earnings updates accompany this report.

Positive

• Regulatory milestone achieved: South Africa’s Competition Commission granted conditional approval, significantly reducing antitrust uncertainty for the Renergen acquisition.

Negative

• Conditions undisclosed: The filing does not specify the required remedies, leaving execution risk.
• Lack of deal economics: No purchase price, financing, or synergy details were provided, limiting valuation clarity.

Insights

M&A Specialist

TL;DR: Conditional antitrust clearance advances ASPI-Renergen deal; positive milestone but final close still requires meeting regulator’s conditions.

Regulatory approval is the largest external hurdle in cross-border deals. South Africa’s Competition Commission granting conditional clearance materially de-risks the transaction, signalling limited competitive concerns. While conditions are undisclosed, history suggests they are typically behavioural rather than structural when granted at this stage. The absence of price or financing data limits valuation analysis, yet the filing confirms ASPI’s intent to expand its isotope footprint via Renergen’s helium assets. Overall, an accretive step in the M&A timeline.

Risk Analyst

TL;DR: Approval is good, but unknown conditions and missing deal terms leave execution and dilution risks unresolved.

Investors should temper enthusiasm. ‘Conditional’ means ASPI must satisfy requirements that could delay or alter economic returns. The 8-K omits cost, funding structure, and synergy targets, preventing a risk-adjusted assessment of impact on leverage or dilution. Additionally, no mention is made of other jurisdictional clearances that may be necessary. Until conditions are published and financing clarified, the development is neutral-to-modestly positive.

0001921865false00019218652025-07-252025-07-25iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 25, 2025

ASP Isotopes Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41555		87-2618235
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

601 Pennsylvania Avenue NW South Building, Suite 900 Washington, DC		20004
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (202) 756-2245

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01		ASPI		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Item 8.01. Other Events.

On July 25, 2025, ASP Isotopes Inc. (the “Company”) issued a press release announcing the Competition Commission of South Africa has given conditional approval of the Company’s proposed offer to acquire all of the issued ordinary shares of Renergen Limited.  A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference, other than the fifth and sixth paragraphs of the press release.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Press Release, dated July 25, 2025, of ASP Isotopes Inc. announcing the Competition Commission of South Africa has given conditional approval of the Company’s proposed offer to acquire all of the issued ordinary shares of Renergen Limited.
104		Cover Page Interactive Date File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ASP ISOTOPES INC.
Date: July 25, 2025	By:	/s/ Paul Mann
	Name:	Paul Mann
	Title:	Chief Executive Officer

3

FAQ

What did ASP Isotopes (ASPI) announce on July 25, 2025?

ASPI reported that South Africa’s Competition Commission conditionally approved its proposed acquisition of all ordinary shares of Renergen Limited.

Which regulatory body approved the ASPI-Renergen deal?

The Competition Commission of South Africa granted conditional approval.

Are there conditions attached to the approval?

Yes. The clearance is conditional, but specific requirements are not disclosed in the 8-K.

Does the filing disclose the purchase price or financing terms?

No. The 8-K contains no information on price, funding structure, or expected synergies.

Where can investors find the related press release?

It is furnished as Exhibit 99.1 to the 8-K, except for its fifth and sixth paragraphs.

Are any financial statements included in this 8-K?

No financial statements or earnings data were provided in the filing.